Nov. 21 at 5:32 PM
$LUD Mainz Biomed The PancAlert story is what really blows my mind: early feasibility data showed ~100% sensitivity and ~95–98% specificity for pancreatic cancer across roughly 30 patients, plus up to 50% of the development costs are covered by a regional innovation grant in Germany, so I see a second engine on top of CRC and for me that justifies a stretch price target of
$15, which is roughly +1 400–1 500% from ~
$0.95 if the validation scales